Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study

• DOI: 10.1016/j.clml.2021.12.009
• Publication Date: 2021-12-13T17:05:20Z
• Authors: Virginia Abello; William Armando M...; Henry Idrobo; Claudia Lucia Sossa; Luis Antonio Salazar; Angela Pena; Juan Manuel Herrera; Paola Guerrero; Daniel Espinosa; Guillermo Enrique...; Isabel Munevar; Kenny Galvez; Alicia Henao; Rigoberto Gómez; Jose Domingo Saav...; Lina María Gaviria; Mónica Osuna; María Victoria Ma...
• Keywords: Autologous stem-cell transplantation

Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America available, and access to novel agents for substantial portion the population limited by their high costs.RENEHOC bidirectional (retrospective prospective) multicenter observational registry hematological malignancies Colombia. patients included up July 2020 were analyzed on this report.890 are reported with median follow-up 18 months (IQR: 7-42 months). Patients classified age group (≤ or > 65 years). Median at diagnosis was 67 years 59-75 years) 47.1% women. 709 (79.6%) received Bortezomib-based schemes as part first line. Two hundred fifty-two (28.3%) consolidated Autologous Stem Cell Transplantation (ASCT) first-line. ASCT consolidation main independent factors influencing outcomes; non-ASCT cohort, 5-year overall survival 48.7% (CI 41.8-55.2) compared 80.7% 73-86.4) patients.This depicts reality Colombia, which likely reflects other American countries, where barriers echoed advanced stage low rate transplants. These seem negatively impact despite availability most drugs approved disease. Thus, emphasizing paradox prevails region: without equitable access.